Though I’m an immunologist at heart, I’ve have been curious about anything biological. I received my PhD from University of Toronto under the mentorship of Dr. Pamela Ohashi (Ontario Cancer Institute, Princess Margaret Hospital) where I studied T cell receptor/ peptide-MHC interactions and intracellular signal transduction pathways governing T cell positive and negative selection in the thymus. Subsequently, I joined the laboratory of Dr. Vishva Dixit at Genentech for my postdoctoral studies, where we elucidated the roles of multiple inflammasome components such as ASC, NALP3, NLRC4 that are critical mediators of Caspase-1-dependent cytokine (IL-1beta, IL-18) release.
In 2007, I joined the nascent Infectious Diseases Department where I led a discovery research team on Antibody-Antibiotic-Conjugates (AACs) – a novel therapeutic platform for invasive Staphylococcus aureus infections. The AAC project is currently in Phase I clinical trials. During my tenure at the Infectious Diseases Department, my lab also supported some of the early discovery efforts on the anti-PD-L1 program.
I’m now a Senior Scientist in the Oncology Biomarker Department and my group is currently focusing on biomarkers associated with efficacy and resistance to anti-PD-L1 cancer immunotherapy.
This is a unique and rare opportunity for a post-doctoral fellow to analyze first-hand data from on-going clinical trials with respect to mechanisms of efficacy and resistance cancer immunotherapy molecules. The position also has plenty opportunities to interact and collaborate with scientists in a dynamic cancer immunotherapy community at Genentech (South San Francisco campus).
Lancet. 2016 May 7;387(10031):1909-20.
Nature. 2015 Nov 19;527(7578):323-8.